Abstract. The role of trefoil factor 3 (intestinal) (TFF3) has been analyzed in numerous cancers, such as breast and gastrointestinal cancer, and has been associated with poor prognosis. However, the role of TFF3 in ovarian cancers is not clear. Expression analysis of TFF3 in 91 ovarian cancer patients was performed by immunohistochemistry of primary paraffin-embedded tumor samples. The results were scored according to staining intensity and percentage of positive tumor cells resulting in an immune-reactive score (IRS) of 0-12. These results were correlated with clinicopathological characteristics and survival. TFF3 expression in our patient cohort exhibited a tendency towards improved overall and progression-free survival (PFS). In TFF3-positive serous and high-grade serous ovarian cancers, the median PFS was 27.6 months [��� confi -��� confidence interval (CI): 0-55.7] vs. 15.2 months in TFF3-negative tumors (95% CI: 13.8-16.6) (P=0.183). The median overall survival was 53.9 months in TFF3-positive tumors (95% CI: Non-applicable) vs. 44.4 months in TFF3-negative cases (��� CI: 30.�-�8.3) (P= 0.36). TFF3 negativity was significantly associated with higher tumor grade (P=0.05). Based on our results, further studies are required in order to elucidate whether survival and chemosensitivity are affected by TFF3 expression in ovarian cancer.
Introduction
Epithelial ovarian cancer (EOC) is the fifth most common lethal cancer in women. The majority of the patients present with advanced-stage disease and, therefore, an unfavorable prognosis (1) . EOC is not a single disease entity. Histological subtyping is a reasonable first stratification; however, the identification of prognostic and predictive biomarkers remains a major challenge in order to establish targeted therapies. The five major histological/morphological types of ovarian carcinoma are as follows: High-grade serous carcinoma (68%), clear cell (12%), endometrioid (11%), mucinous (3%) and low-grade serous carcinoma (3%) (2) .
Despite high response rates to first-line chemotherapy, resistance to treatment frequently develops. Indeed, ~80% of the patients with International Federation of Gynecology and Obstetrics (FIGO) stage II-IV EOC will progress during or after adjuvant chemotherapy (3) . Therefore, there is a need for new therapeutic approaches, as well as prognostic and predictive markers. Identification of new prognostic factors may help to distinguish different biological subgroups. In EOC, this is particularly important for the group of patients who develop recurrent disease. These patients often do not benefit from current treatment modalities and may suffer from severe therapy-related side effects. Future research should be focused on establishing more targeted and individualized treatment strategies in biologically distinct subgroups.
Trefoil factor 3 (TFF3) is an estrogen-regulated oncogene (4) . TFF3 expression has been found to be associated with prognostic factors in a multitude of different types of cancer, including estrogen receptor-positive breast cancer (4) . Furthermore, TFF3 has been found to be involved in gastric cancer progression (5) . TFF3 is part of the marker panel that was selected for the calculator for ovarian carcinoma subtype prediction, introduced by Kölbel et al in 2011, as being most predictive of ovarian carcinoma subtype in both the archival and the tumor bank cohorts (2) . The selection of TFF3 was based on comprehensive gene expression profiling data (2, 6) . To the best of our knowledge, data on TFF3 in ovarian cancer are scarce. Therefore, the expression of the TFF3 in 91 ovarian cancer patients was investigated to determine its effect on prognosis and platinum sensitivity in ovarian cancer. Statistical analysis. For statistical analysis a cut-off value was defined according to the IRS, i.e., scores of 0-3 (negative and low) were collectively defined as a low score, whereas scores ≥3 were defined as a high TFF3 expression score. The Chi-square and Fisher's exact tests were used to assess the associations between TFF3 expression of tumors and clinicopathological parameters. For those patients with available follow-up data, Kaplan-Meier curves were constructed and the log-rank test was used to determine the univariate significance of the variables. Cox regression analysis was performed to determine hazard ratios. All reported P-values were two-sided and P-values of ≤0.0� were considered to indicate statistically significant differences. All analyses were performed using the SPSS software package, version 22.0 (IBM SPSS, Armonk, NY, USA).
Patients and methods

Patients
Results
Patient characteristics.
A total of 91 patients were included in this study. All the patients underwent primary debulking surgery including hysterectomy, bilateral salpingo-oophorectomy, infragastric omentectomy, appendectomy (mucinous subtype), systematic pelvic and para-aortic lymphadenectomy and, in distinct cases, peritonectomy and resection of affected tissues with intended resection of all visible tumors. In the majority of the patients (n=62; 68�) optimal debulking, i.e., achieving an optimal postoperative residual tumor of ≤1 cm, according to the National Comprehensive Cancer Network guidelines (11), could be achieved. The median follow-up time was 33 months. The Kaplan-Meier estimate for median progression-free survival (PFS) for the entire group was 16.9 months [95% confidence interval (CI): 14.0-19.7] and for overall survival (OS) 51.6 months (95% CI: 42.9-60.2). The corresponding 5-year PFS and OS rates were 17.9±5.1 and 34.9±6.2%, respectively. In Among TFF3-negative tumors (IRS=0-3), 25.8% were G1 or G2 and 74.2% were G3, while among TFF3-positive tumors, grade was equally distributed between the two groups (48 vs. 52%, respectively). The correlation of TFF3 negativity with higher grade was statistically significant (P=0.05 Fisher's exact test; Table II) .
Association of TFF3 expression with survival. In the Kaplan-Meier analysis of the entire cohort, the median PFS and OS were increased in TFF3-positive patients ( Figs. 1  and 2 ). However, this was statistically not significant (P= 0.1�1 and P= 0.1��, respectively; log-rank Mantel-Cox) although there was a trend for a better PFS.
In the entire group, the median PFS in TFF3-positive patients was 27.6 months (95% CI: 1.4-53.8) vs. 15.6 months (95% CI: 13.6-17.6) in TFF3-negative patients. The OS for the entire group in TFF3-positive patients was 75.1 months (95% CI: 40.4-109.8) vs. 45.8 months (95% CI: 30.5-61.6) in TFF3-negative cases.
By analyzing the subgroups of serous (n=70) and high-grade serous (n=62) ovarian carcinomas, the trend for a better PFS and OS in patients with high expression of TFF3 was confirmed. For the subgroup of high-grade serous ovarian cancer (n=62), the PFS (P=0. Univariate Cox regression analysis. The univariate Cox regression analysis revealed a statistically significant effect of residual tumor on OS and PFS (P<0.001 and P<0.001, respectively) and of FIGO stage on OS and PFS (P=0.001 and P<0.001, respectively). However, TFF3 positivity did not exert an effect on OS and PFS in the univariate Cox regression analysis (P=0.158 and P=0.156, respectively) (Table III) .
Multivariate Cox regression analysis. The multivariate Cox regression analysis for OS and PFS included age (>�0 vs. ≤�0 years), grade (G1 or G2 vs. G3), FIGO stage (I and II vs. III and IV), pathology (serous vs. others) and residual tumor (0 vs. >0 cm). Only FIGO stage and residual tumor exhibited a statistically significant correlation with poor OS (P=0.041 and P=0.043, respectively). TFF3 expression was not found to be significantly correlated with PFS or OS in all patients in the multivariate analysis (P=0.249) (Table IV) .
Discussion
Ovarian carcinomas of different histological types originate from different precursor cells; thus, they retain specific gene and biomarker expression profiles (2) . Ovarian cancer subtyping remains one of the major challenges in order to establish prognostic and predictive markers. Apart from histological subtype and the recently established binary grading system that forms subgroups of high-grade and low-grade serous EOC, very few predictive or prognostic biomarkers have been identified in order to better describe the clinical course of the disease, as well as sensitivity to different therapeutic approaches. Furthermore, genetic tumor profiling may reveal several prognostic and predictive genetic signatures. However, these signatures have yet to be validated. In this context, TFF3 was found to be involved in certain signatures. The TFF family, which comprises three proteins (TFF1, TFF2 and TFF3), is involved in the development and progression of various types of cancers (12) .
However, the role of TFF3 in ovarian cancer has not been fully elucidated (13) . In breast cancer cells, TFF3 expression is generally positively associated with mammary carcinoma of the estrogen receptor-positive subtype, and TFF3 was recently identified as a promoter of tumor angiogenesis (4). In breast cancer, TFF3 expression is associated with poor survival, lymph node dissemination and distant metastasis. Furthermore, TFF3 may promote gastric cancer and its expression is associated with increased microvessel density in gastric as well as breast cancer (4, 5) . High TFF3 mRNA levels in colorectal cancer tissues are associated with distant metastasis, recurrence and poor survival (12) . Other authors investigated serum TFF3 levels in gastrointestinal cancer patients and found a correlation of high serum levels with advanced-stage disease and poor response to chemotherapy (12) . TFF3 is an estrogen receptor-related gene in breast and ovarian cancer. Apart from the effect of TFF3 on endocrine therapy, TFF3 expression may also be associated with chemoresistance in breast cancer (14) . As immunohistochemical staining of the estrogen receptor does not affect the clinical management of ovarian cancer, it is not part of the routine histopathological work-up of ovarian cancer. Thus, in the present study, we did not focus on the correlation of TFF3 expression with the estrogen receptor. However, further studies are required in order to elucidate the effect of simultaneous estrogen receptor and TFF3 expression in ovarian cancer.
This retrospective analysis of 91 patients with EOC shows that loss of TFF3 expression may be correlated with disease progression. To the best of our knowledge, this is the first report on the prognostic effect of TFF3 expression in this tumor entity.
Interestingly, in our patient collective, there was a trend for improved prognosis in TFF3-positive patients; however, this trend was not significant (P= 0.1�1 and P= 0.1�� for OS and PFS, respectively). This tendency of differences in OS and PFS in TFF3-positive vs. -negative patients appears to be contradictory to the results of other tumor entities, which reported TFF3 to be a marker of poor prognosis (12) . Above all, however, TFF3 positivity may be associated with higher chemosensitivity, which may explain the improved survival due to a better response to chemotherapy. In our patient collective, no significant correlation was observed between TFF3 expression and sensitivity to platinum agents. In order to elucidate this question, in vitro essays and further studies are required. In our patient collective, all histopathological subtypes were included. However, histological subtypes other than serous EOC were underrepresented. Under the assumption that TFF3 is part of the subtype markers for different histopathological entities of ovarian cancer, larger studies are required in order to clearly differentiate between the different histological subtypes (2) . In particular, the subgroup of mucinous EOC should be further investigated due to its similarities to gastrointestinal tumors. Based on the dualistic model of ovarian carcinogenesis proposed by Kurman and Shih, we performed a subgroup analysis of high-grade serous ovarian cancers (type II tumors) (16) . In our patient collective, the subgroup analyses of high-grade serous ovarian cancers yielded identical results. However, these results must be interpreted with caution, as the differences in OS and PFS between TFF3-positive and -negative patients were not significant. A significant difference in TFF3 expression based on grade (G1 or 2 vs. G3) was observed, namely G3 tumors were less likely to express TFF3 (P= 0.0�). To the best of our knowledge, there are no reported data on a correlation between grade and TFF3 overexpression to date. Further studies with larger patient collectives and subgroup analyses are required, as our patient collective was heterogeneous regarding histological subtype, stage and therapy.
